Tel: +263 242 708020, +263 242 705946 info@uzchsrsc.ac.zw

Funding Opportunities

Fellowships and Scholarships

Call for applications TDR Clinical Research Leadership fellowship programme

TDR will fund fellows employed by academic and research institutions in any low- and middle-income country across the globe (not limited to those in sub-Saharan Africa) to be placed in pharmaceutical companies, product development partnerships (PDPs) and academic-affiliated research organizations, in Africa, America, Asia, Europe and Latin America, to train and develop new research skills on infectious diseases. Successful applicants are placed from 6 to 12 months in Training Partner Organisations (TPOs) and receive a reintegration plan for 12 months at their home institutions. Fellowship duration will be based on the proposed targeted training offered by each TPO.

Deadline for applications:  19 February 2024 at 17:00 (CET)

For more information, click: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/file:///Users/thokozilemashaah/Downloads/final-call-2024-crl.pdf

 

Georg Forster Research Fellowship for Sustainable Development

The Alexander von Humboldt Foundation grants the Georg Forster Research Fellowship to researchers in all disciplines from developing and emerging countries (see list of countries, PDF) who have above-average qualifications. With this fellowship the Humboldt Foundation acknowledges the important role of researchers from these countries in achieving the UN’s 17 sustainable development goals and thus provides them with sponsorship that is equivalent to the Humboldt Research Fellowship. The Georg Forster Research Fellowship enables you to conduct your own research at various stages of your career in collaboration with a host at a German research institution of your choice.

Application deadlines: The Selection Committee responsible for reviewing applications to this programme meets every February, June and October.

For more information click: https://www.humboldt-foundation.de/en/apply/sponsorship-programmes/georg-forster-research-fellowship

Stanford African Scholars in Global Health Program

The Stanford Center for Innovation in Global Health is pleased to announce that applications will open on Feb. 5, 2024 for the first two cohorts of the Stanford African Scholars in Global Health (SASH) program.

For this unique fellowship focused on bidirectional learning and equitable partnerships, selected fellows will spend six weeks at Stanford during the 2024-25 academic year to develop a skill to help improve a specific health outcome at their institution. Cohort 1 will be at Stanford January – February 2025; Cohort 2 will travel from April – May 2025. While at Stanford, fellows will be appointed as Visiting Instructors and will have the opportunity to earn Continuing Medical Education credit. They will then receive a generous Pfizer grant of up to $50,000 and ongoing mentorship for 12-18 months to implement a clinical improvement project at their home institution, building upon the skills developed at Stanford. The fellowship will culminate with a presentation at a convening to be held in an African country at a later date.

Deadline: February 25, 2024

For more information click: https://globalhealth.stanford.edu/education/applications-for-the-stanford-african-scholars-in-global-health-program-open-feb-5.html/

 

Call for Applications: Postdoctoral & PhD Research Fellowships in Population Health Innovation

Stellenbosch University (SU) is firmly committed to the pursuit of knowledge, research and innovation, in service of society. We provide a world-class centre for learning and development, which is globally relevant, yet rooted in the upliftment and transformation of our local communities.  The Population Health Innovation program at the Centre for Epidemic Response and Innovation (CERI)  is currently seeking to employ outstanding post-doctoral and PhD researchers to undertake cutting edge research in three areas:

  • Quantification of the shifts in burden of HIV incidence and underlying viral load patterns in a full population cohort in KwaZulu-Natal, South Africa
  • A cluster randomized controlled trial to increase uptake of HIV pre-exposure prophylaxis among men in Eastern Zimbabwe
  • Use of mobile phone GPS trace data for predicting HIV risk among mobile populations.

Minimum requirements for the Postdoctoral research fellowships:

  • PhD in Biostatistics, Epidemiology, Econometrics, Data Science, Geography, Mathematical Modelling or a closely related quantitative field
  • Several high-quality publications as a first author
  • PhD must have been obtained within the last 5 years

Minimum requirement for the PhD fellowships:

  • Masters in Biostatistics, Epidemiology, Econometrics, Data Science, Geography, Mathematical Modelling or a closely related quantitative field

For more information, contact Prof. Frank Tanser ftanser@sun.ac.za

Deadline for applications: 1st March 2024

For more information click: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/file:///Users/thokozilemashaah/Downloads/2024%20Postdocs%20advert%20PHP.pdf

 

OWSD Early Career Fellowship – The 2024 Call for Applications is now open.

The OWSD Early Career Fellowship is a prestigious award of up to USD 50,000 offered to women who have completed their PhDs in Science, Technology, Engineering and Mathematics (STEM) subjects and are employed at an academic or scientific research institute in one of the listed Science and Technology Lagging Countries (STLCs). The OWSD Early Career fellows are supported to establish environments at their institutions where they can maintain an international standard of research and attract scholars from all over the world to collaborate.

Deadline for completed online applications: 14 March 2024 (at 23:59 Rome time)

For more information click; https://owsd.net/career-development/early-career-women-scientists-ecws-fellowships

 

L’Oréal-UNESCO L’Oréal For Women in Science Young Talent program Sub-Saharan Africa – Call for Application 2024

The Fondation L’Oréal and UNESCO launch the 15th edition of the L’Oréal-UNESCO For Women in Science Young Talents – Sub-Saharan Africa program, to support young women scientists. In 2024, 30 endowments will be offered for the Sub-Saharan Africa region: Doctorate: €10 000 Post-doctorate: €15 000

Deadline for applications: 15 March 2024

For more information click: https://www.forwomeninscience.com/challenge/show/92

Global Grand Challenges: Strengthening African National Regulatory Authorities Data Systems to Enhance and Track Performance

Applications are invited from African National Regulatory Agencies (NRAs). Each proposal should be submitted by one primary applicant, but the awards require active collaboration between at least two NRAs per application. In addition, proposals should address at least two (2) of the following categories:

Regulatory review process management:

  • Create or improve regulatory digital data management systems and end-to-end processes including structured approaches to data generation, analysis, sharing at the regional level. and reporting of KPIs. Priority will be given to proposals including a solid plan for reporting on KPIs, this includes:
    1. regulatory timelines for national marketing authorization,
    2. clinical trial applications,
    3. facilitated regulatory pathways; we would prioritize proposals including REC products, WHO PQ CRP, global pathway (and AMA pathways in future)
  • Design and structure data management systems that contribute to NRAs achieving WHO ML3/WLA status along with other important efforts addressing the rest of the GBT requirement outside of performance management.

Applications closing deadline: January 31, 2024

For more information, click: https://gcgh.grandchallenges.org/challenge/strengthening-african-national-regulatory-authorities-data-systems-enhance-and-track

 

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Applications closing deadline: February 5, 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-105.html

Microbial-based Cancer Imaging and Therapy – Bugs as Drugs (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics. Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This FOA will support basic mechanistic and preclinical studies in cell culture and animal models. Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis.

Applications closing deadline: February 5, 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-085.html

Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support training and educational activities for responsible analyses of complex large-scale data involving brain, behavioral, genomic, and socioenvironmental data that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs.

  • Courses for Skills Development
  • Curriculum or Methods Development

Applications closing deadline: 8 February 2024

For more information, click: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-027.html

 

NSF-Mercury Project Partnership

A pathbreaking $20 million partnership with the National Science Foundation is advancing the scientific frontier of building vaccination demand and a healthier information environment. The Mercury Project is proud to join with the National Science Foundation in a path-breaking $20M partnership to support social and behavioral science R&D designed to identify interventions with the potential to increase vaccination demand and other health behaviors grounded in science-based public health guidance. This innovative partnership will support research teams seeking to evaluate online or offline interventions to increase vaccination demand and other positive health behaviors, including by targeting the producers and/or consumers of inaccurate health information and/or by increasing confidence in reliable health information. We welcome proposals for evaluations sited in the United States, Africa, Asia, and/or Latin America and the Caribbean.

To apply for funding through the NSF-Mercury Project partnership, investigators may apply to any of the NSF programs. Proposals should adhere to NSF program deadlines and submission requirements, including the proposal preparation guidelines contained in the NSF Proposal & Award Policies & Procedures Guide (PAPPG).

For more information on the NSF programs and deadlines click: https://www.ssrc.org/programs/the-mercury-project/nsf-mercury-project-partnership/

 

Innovations to Prepare for Future Epidemics and Pandemics

CEPI’s Innovations to Prepare for Future Epidemics and Pandemics Call for Proposals aims to support CEPI’s mission by advancing a broad range of vaccine innovations for pathogens with epidemic or pandemic potential, including novel pathogens capable of infecting and causing disease in humans (i.e., Disease X). It will support vaccine research, development and manufacturing innovations for CEPI’s priority pathogens and contribute towards the 100 Days Mission, thereby helping the world prepare for known and future epidemic and pandemic threats. It initially invites applications across three Focus Areas:

  • Focus Area 1: advancing innovative rapid-response vaccine platforms that can transform the response to a future Disease X.
  • Focus Area 2: developing new vaccine candidates against CEPI priority pathogens with epidemic or pandemic potential and viral families.
  • Focus Area 3: advancing manufacturing innovations that improve vaccine scalability and equitable access.

Application deadlines: CEPI welcomes proposals for Focus Areas 1 and 2 on a rolling basis through 2026. Proposals for Focus Area 3 can be submitted through 12 February 2024. Call deadlines may be subject to amendment.

For more information click: https://cepi.net/get_involved/cfps/?swcfpc=1&learn-more-9166=2

 

National Eye Institute (NEI) Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed)

The NEI supports large-scale clinical vision research projects, including randomized clinical trials and epidemiologic studies on eye/vision conditions. At the time of submission, applications requesting support for these activities are expected to provide detailed information regarding the study rationale, design, analytic techniques, protocols and procedures, facilities and environment, organizational structure, and collaborative arrangements. This information is best conveyed in a Manual of Procedures (MOP), the development of which represents a costly and time-consuming activity. This clinical research planning grant funding opportunity supports applicants in their planning efforts to conduct collaborative clinical research. The grant may be used to support the development of a MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential. The grant must not be used to generate data on the effects of a proposed intervention. This NEI FOA is applicable to both epidemiologic and clinical trial research studies.

Application deadline: 16 February 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-128.html

 

Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Applications appropriate to this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR).

Applications closing deadline: 7 January 2024

For more information, click: https://grants.nih.gov/grants/guide/pa-files/PAR-21-068.html

 

Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

This FOA encourages applications at the intersection of HIV and aging by addressing two overarching objectives: 1) to improve understanding of biological, clinical, and socio-behavioral aspects of aging through the lens of HIV infection and its treatment; and 2) to improve approaches for testing, prevention, and treatment of HIV infection, and management of HIV-related comorbidities, co-infections, and complications in different populations and cultural settings by applying our current understanding of aging science. Studies that move the science of HIV and aging into new directions with little or no preliminary data are appropriate for this activity code. Applications appropriate for this FOA should be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR).

Applications closing deadline: 7 January 2024

For more information, click: https://grants.nih.gov/grants/guide/pa-files/PAR-21-069.html

 

Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support training and educational activities for responsible analyses of complex large-scale data involving brain, behavioral, genomic, and socioenvironmental data that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral, and clinical research needs.

  • Courses for Skills Development
  • Curriculum or Methods Development

Applications closing deadline: 8 February 2024

For more information, click: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-027.html

 

 

NSF-Mercury Project Partnership

A pathbreaking $20 million partnership with the National Science Foundation is advancing the scientific frontier of building vaccination demand and a healthier information environment. The Mercury Project is proud to join with the National Science Foundation in a path-breaking $20M partnership to support social and behavioral science R&D designed to identify interventions with the potential to increase vaccination demand and other health behaviors grounded in science-based public health guidance. This innovative partnership will support research teams seeking to evaluate online or offline interventions to increase vaccination demand and other positive health behaviors, including by targeting the producers and/or consumers of inaccurate health information and/or by increasing confidence in reliable health information. We welcome proposals for evaluations sited in the United States, Africa, Asia, and/or Latin America and the Caribbean.

To apply for funding through the NSF-Mercury Project partnership, investigators may apply to any of the NSF programs. Proposals should adhere to NSF program deadlines and submission requirements, including the proposal preparation guidelines contained in the NSF Proposal & Award Policies & Procedures Guide (PAPPG).

For more information on the NSF programs and deadlines click: https://www.ssrc.org/programs/the-mercury-project/nsf-mercury-project-partnership/

 

Gilead giving in Africa

Grant making in Africa focuses on HIV/AIDS and Viral Hepatitis. Within these therapeutic areas, we provide support for a broad range of activities, including disease awareness; disease prevention; professional education; improving patient access to care; improving quality of care; increasing scientific capacity; strengthening healthcare systems. Across the continent, Gilead works with a number of local partners to help ensure that our medicines reach the people that need them. Our pioneering generic licensing agreements have played a central role in expanding access to high-quality, low-cost HIV treatment throughout Africa.

Grant applications are accepted throughout the year. Funding requests must be submitted a minimum of 8 weeks prior to the start of the activity. The typical grant review timeline can be up to 12 weeks. Formal notifications of all funding decisions are sent in writing by email to the contact listed on the grant application.

For more information click: https://www.gilead.com/purpose/giving/funding-requests/apply-africa

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA’s current portfolio that has the potential to transform SUD research. The proposed research should: 1. develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research; and /or 2. test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking.

Due date: 8 March 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-21-208.html

 

Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 – Clinical Trial Optional)

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, and/or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.

Due date: 22 March 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-23-318.html

 

Climate Impacts Awards: Unlocking urgent climate action by making the health effects of climate change visible

The aim of this scheme is to make the impacts of climate change on physical and mental health visible to drive urgent climate policy action at scale. We will fund transdisciplinary teams to deliver short-term, high-impact projects that maximise policy outcomes by combining evidence generation, policy analysis, engaged research approaches and communication strategies.

Career stage: Mid-career researcher, Established researcher

Where your administering organisation is based: Anywhere in the world (apart from mainland China)

Level of funding: Up to £2.5 million

Duration of funding: Up to 3 years

Due date: 3 April 2024

For more information click: https://wellcome.org/grant-funding/schemes/climate-impacts-awards

 

Request for Applications (RFA): HIV Cure-Related Research in Africa

This announcement invites application(s) from research institution located in Africa to submit research proposals that will (1) support HIV cure-related research in areas of Africa in which there is a high proportion of people living with HIV and (2), expand our understanding of the persistence of non-subtype B HIV in people on antiretroviral therapy (ART) and the mechanisms of post-treatment control of viremia following cessation of ART. The announcement will fund awards of no more than $150,000 per applicant for direct costs for one year. For the purposes of this Competition, applicants should propose projects in the following areas, but not limited to:

  1. Developing and optimizing assays to quantify the levels of full-length, intact HIV proviral DNA in individuals living with non-subtype B HIV and to determine the proportion of intact, rebound competent, and defective provirus
  2. Understanding the virology of the rebound-competent persistent proviral HIV reservoir
  3. Establishment, tissue and cell type distribution
  4. Dynamics, including the clonal proliferation of cells harboring HIV provirus and their decay over time
  5. Studies of the innate and adaptive immune responses to HIV in people living with non-subtype B on ART and the relation of these responses to the rebound-competent viral reservoir, including the sensitivity of the intact reservoir to circulating autologous antibodies and existing T cell responses
  6. Frequency and mechanism of post treatment control in for people living with non-subtype B HIV

Application deadline: 15 April 2024

For more information, click: https://www.crdfglobal.org/funding-opportunities/hiv-cure-related-research-in-africa/ or chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.crdfglobal.org/wp-content/uploads/2024/01/HIV-Cure_Request-For-Applications.pdf

 

Wellcome Career Development Awards

This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding that could improve human life, health and wellbeing.

Career stage: Mid-career researcher

Where your administering organisation is based: UK, Republic of Ireland, Low- or middle-income countries (apart from India and mainland China)

Level of funding: You should ask for your salary (if required) and the resources you need for your research programme – see the ‘What we offer’ section on this page. You will need to justify this in your application.

Duration of funding: Usually 8 years, but may be less for some disciplines and may only be longer if held on a part-time basis.

Application deadline: 11 April 2024

For more information, click: https://wellcome.org/grant-funding/schemes/career-development-awards

Wellcome Discovery Awards

This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding that could improve human life, health and wellbeing.

Career stage: Established researcher

Where your administering organisation is based: UK, Republic of Ireland, Low- or middle-income countries (apart from India and mainland China)

Level of funding: You should ask for the resources you need for your research programme – see the ‘What we offer’ section on this page. You will need to justify this in your application. The average size of a Discovery Award is £3.5 million, although we have supported awards from £700,000 to £8 million. Applications above £5 million will be subject to additional due diligence.

Duration of funding: Awards can be up to 8 years, but may be less for some disciplines, and may be longer if held on a part-time basis. The average duration of a Discovery Award is 7 years, although we have supported awards from 3 to 8 years.

Application deadline: 16 April 2024

For more information, click: https://wellcome.org/grant-funding/schemes/discovery-awards

 

African Research Leaders

Apply for funding to support exceptional early to mid-career African researchers to conduct excellent global health research across sub-Saharan Africa (SSA). Researchers should be supported by an enthusiastic local research environment and by a UK-based partner as part of a partnership between the African and UK institutions. We aim to attract and retain exceptionally talented ‘rising star’ individuals who will lead high quality research on key global health issues pertinent to SSA. Awards will provide support for up to five years and the requested amount should not exceed £750,000 in total. African researchers who already have a well-established record of securing significant international research grant funding or have reached a level of seniority (for example, professor or head of department) should not apply to this funding opportunity.

Application deadline: 24 April 2024

For more information click: https://www.ukri.org/opportunity/african-research-leaders/

Bioimaging Technology Development Awards

This award will fund teams of technology developers and users to create novel bioimaging tools at the cell-tissue scale. Successful teams will develop technologies that answer ambitious research questions or that overcome barriers to bioimaging work in low-resource settings.

Career stage: Leading a research programme

Where your administering organisation is based: UK, Republic of Ireland, Low- or middle-income countries (apart from India and mainland China)

Level of funding: Foundation phase: up to £500k; Scale-up phase: you should ask for the resources you need for your programme – see the ‘What we offer’ section on this page. You will need to justify this in your application.

Duration of funding: Up to 8 years, spanning two phases: a foundation phase for the first 18 months, followed by a scale-up phase up to a maximum of 6.5 additional years.

Application deadline: 30 April 2024

For more information click: https://wellcome.org/grant-funding/schemes/bioimaging-technology-development-awards

 

 

Improving Breast Cancer (BC) Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa

Conquer Cancer®, the ASCO Foundation and Pfizer Global Medical Grants are collaborating to offer a Quality Improvement grant funding opportunity to improve the quality of care and to help build capacity to address the needs of breast cancer (BC) patients in Sub-Saharan Africa. This grant program will support innovative projects to improve the quality of BC patient care in the select geographies in the region (please review eligibility section below).   Submissions addressing the expressed Areas of Interest with a measurable and sustainable positive impact on patients will be favored by the Scientific Review Committee (SRC).   This grant awards program was purposefully developed with the Sub-Saharan Africa Regional Council of ASCO expressly for the patients of the Sub-Saharan region.  Conquer Cancer is the lead organization for the review and evaluation of applications. Grant funding will be provided directly from Pfizer. Collectively, up to $1,000,000 is available to fund Quality Improvement projects under this RFP. The maximum grant budget is $80,000 with a term of 24 months.

Due dates: 11 March 2024

For more information click: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cdn.pfizer.com/pfizercom/2024-01/GMG_2024-ONC-SSA_ASCOCCFBCQI_English.pdf?VersionId=2CT7P5M9zMAL45uH_NG0Kp1FSCOr8lt1

 

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Due dates: 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-109.html

 

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.

Due dates: 16 Feb, 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-106.html

 

NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed)

This FOA encourages applications from institutions/organizations that propose to conduct vision-related secondary data analyses utilizing existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports an extensive portfolio of clinical trials and large-scale epidemiologic research projects wherein numerous data collection activities are required to meet each project’s specific aims. The resultant wealth of data generated by these studies often provides unique, cost-effective opportunities to investigate additional research questions or develop new analytical approaches secondary to a project’s originally-intended purpose. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data.

Due dates: 16 Feb, 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-22-141.html

 

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects.Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. Access to these data will promote comprehensive and cross-cutting research and collaboration leading to more refined diagnostic capabilities and ultimately more targeted therapies. This FOA is intended to support meritorious small research projects focused on analyses of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets. Development of approaches, tools, or algorithms appropriate for analyzing genomic, phenotypic, and/or clinical data relevant to Kids First may also be proposed.

Due dates: 16 Feb, 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-23-075.html

 

Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)

The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.

Due dates: 16 Feb, 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-23-301.html

Alcohol Health Services Research (R34 Clinical Trial Optional)

The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This NOFO will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

Due dates: 16 Feb, 16 June and 16 Oct 2024

For more information click: https://grants.nih.gov/grants/guide/pa-files/PAR-23-252.html

 

 

 

For Expired funding opportunities:

  Click here

CONTACT US

University of Zimbabwe
Faculty of Medicine and Health Sciences
Research Support Centre
Parirenyatwa Hospital Grounds

Tel: +263 242 708020, +263 242 705946

Email address

rscsacoreoffice@gmail.com

rsc@medsch.uz.ac.zw

Website

www.uzchsrsc.ac.zw

 Twitter

ttps://twitter.com/UZCHSRSC

Linkedin

https://www.linkedin.com/in/uz-fmhs-research-support-centre-995768267/

Research Support Centre